Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
HBM1020, generated from Harbour Mice® H2L2 transgenic mice platform, is the first therapeutic monoclonal antibody against B7H7/HHLA2 to have entered clinical development globally. Data from the dose-escalation study of a phase I, multi-center, open-label trial (NCT05824663) demonstrated the promising safety and tolerability profiles of HBM1020 in patients with advanced solid tumors.
The findings will be displayed as a poster presentation during the
Title: Ph I Dose-Escalation Study of HBM1020, a Novel Anti-B7H7 Antibody in Patients with Advanced Solid Tumors
Presentation Number: 1010P
Onsite Poster Display Date:
Speaker: Jason Henry
All accepted abstracts will be published online on the ESMO website.
About HBM1020
HBM1020 is a first-in-class fully human monoclonal antibody generated from Harbour Mice® H2L2 transgenic mice platform, targeting B7H7/HHLA2.
B7H7, also known as HHLA2, is a novel immune modulatory molecule belonging to the B7 family. The B7 family is of central importance in regulating the T-cell response, making these pathways very attractive in cancer immunotherapy. Most of the validated targets in immune-oncology so far are related to B7 family, including PD-(L)1, and CTLA-4. The therapies against B7 family targets have already shifted the paradigm for cancer therapy with outstanding clinical benefits. As a newly discovered member of the B7 family, B7H7 expression is found non-overlapping with PD-L1 expression in multiple tumor types, which indicates an alternative immune evasion pathway besides PD-(L)1. In PD-L1 negative/ refractory patients, B7H7 potentially plays a critical role for tumor cells to escape immune surveillance. HBM1020 can enhance anti-tumor immunity by blocking the novel immune checkpoint target. Preclinical data demonstrated its immune activation and anti-tumor functional activities.
With its innovative biology mechanisms, HBM1020 presents a novel anti-tumor therapeutics complementary to PD-(L)1 therapeutics to patients, especially for PD-L1 negative/refractory patients.
About Harbour BioMed
Harbour
The proprietary antibody technology platforms Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/harbour-biomed-to-present-the-latest-progress-of-the-first-in-class-fully-human-anti-b7h7hhla2-monoclonal-antibody-hbm1020-at-the-esmo-congress-2024-302207269.html
SOURCE Harbour BioMed